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A β3 adrenoceptor agonist plays an important regulatory role in stimulation of thermogenesis and lipolysis and it 
appears to have anti-ulcer and spasmolytic effects. So the present aim was to examine the effect of BRL 37344 
(a selective B3 adrenoceptor agonist) on reflux esophagitis. Methods: Forty-eight rats were divided into twelve sham-
operated rats and thirty-six rats with induced reflux esophagitis (RE), which were divided into either RE alone or 
pretreated with BRL 37344 and/or omeprazole with or without indomethacin. RE was induced in rats, then gastric 
acid output, pH, plasma nitric oxide (NO), esophageal PGE2, malondialdehyde (MDA) and reduced glutathione 
(GSH) were measured and the esophageal injury was assessed by macro scopic damage score. Results: Pretreatment 
with BRL significantly increased plasma NO, GSH, decreased acid output, esophageal MDA and esophageal injury 
in comparison to pretreatment. In addition, there was a no significant increase in esophageal PGE2. Conclusion: 
It can be concluded that BRL 37344 has an anti-oxidant protective effect in rats with RE.
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Reflux esophagitis is a disease where gastric juices reach the esophagus because of a transient 
lower esophageal sphincter (LES) relaxation, a low esophageal clearance speed, and a lack 
of mucosal resistance (7). Reflux of gastric contents leads to inflammation, ulceration, and 
destruction of the esophagus squamous epithelium (3, 12). This could lead to deleterious 
pathological conditions, as chronic esophagitis, aspiration pneumonia, esophageal strictures, 
and even malignancy in form of Barrett’s esophagus (8).
The severity of reflux esophagitis does not only depend on acid reflux, the impaired 
mucosal resistance is also involved (21). Some studies suggested that oxygen derived free 
radicals in RE induced esophageal muco sal damage leading to mucosal inflammation, and 
the management of these free radicals role and the inflammatory responses associated with, 
may be a potential therapeutic effect in the management of RE (19).
The neural and paracrine systems [cyclooxygenase-prostaglandin (COX-PG)] and nitric 
oxide synthase (NO) are involved in the maintenance of the integrity of epithelial barrier of 
the GIT against aggressive factors (17).
Different receptors are responsible for norepinephrine and epinephrine effects, one of 
them is the β3 adrenergic receptor. Β3 receptors are present in a variety of tissues as brain, 
adipose tissues, stomach, and urinary bladder (11). Beta stimulation produces a delay in 
gastric emptying. In guinea pigs, it induces a cAMP-dependent relaxation of stomach fundus 
(13). In rats, β3 adrenoceptors produce a reduction in acidic secretion due to pentagastrine 
stimulation (1).
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The antiulcer action of β3-adrenoceptor agonists is mediated by a decrease in gastric 
acid secretion, an enhancement of mucin activity and anti oxidant effect in the gastro-duodenal 
region (25).
Proton pump inhibitor, omeprazole is the standard therapeutic drug in acid-related 
disorders as gastro-esophageal reflux disease, Zollinger–Ellison syndrome, and peptic-ulcer 
disease (14). Omeprazole inhibits gastric acid secretion to control the previous disorders 
(27).
The aim of this work was to study the potential biochemical effects of BRL 37344, as 
compared with omeprazole on a rat model of reflux esophagitis.
Materials and Methods
Animals
Forty-eight Sprague–Dawley rats (250–300 g) were housed in standard cages in groups of six 
animals per cage under controlled conditions (temperature 25 ± 10 oC, and a 12:12 light/dark 
cycle), with free access to food and water for 1 week for acclimatization. They were fasted 
for 24 h before the experiment. Drinking water was freely available to the animals up to 
2 hours before the experiment. All procedures were approved by the Medical Research, 
Ethical Committee, Mansoura University, Mansoura, Egypt.
Esophagitis induction
Under ether inhalation anesthesia, the abdomen was incised along the midline and then both 
the pylorus and the junction between the fore stomach and corpus were simultaneously 
ligated according to the method of Nakamura (23). So, the capacity of the stomach to preserve 
the gastric juice was decreased, resulting in gastric juice reflux into the esophagus, a 
longitudinal cardiomyotomy 1 cm of length was performed across the gastro-esophageal 
junction to enhance reflux. The animals were fasted for 36 h after the operation but were 
allowed to tap water ad libitum. Then, after 36 hours, they were sacrificed with an overdose 
of ether, and the esophagus and stom ach was removed as one unit.
Animal groups
Forty-eight rats were divided into the following groups:
– Group one (12 rats): It was included sham-operated rats (control group).
 These rats were further subdivided into:
 1a (six rats): sham-operated rats.
 1b (six rats): sham-operated rats pretreated with indomethacin.
–  Group two (12 rats): Rats in which reflux esophagitis was induced. These rats were 
further subdivided into:
 2a (six rats): Rats with reflux esophagitis alone.
  2b (six rats): Rats with reflux esophagitis were induced + they received indomethacin 
intraperitoneally (5 mg/kg, Nile Parma, Egypt) was given 30 minutes before the start 
of ligation (17).
–  Group three (12 rats): BRL 37344 sodium salt powder (Sigma, USA) dissolved in 
distilled water was given to rats before induction of reflux esophagitis. These rats 
were further subdivided into:
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  3a (six rats): BRL 37344 (1 mg/kg, orally) was given to rats 30 minutes before 
induction of  reflux esophagitis (6).
  3b (six rats): BRL 37344 was given before induction of reflux esophagitis in 
indomethacin treated rats. Rats received BRL 37344 (1 mg/kg orally) followed 30 
minutes later by indomethacin (5 mg/kg intraperitoneally) and finally 30 minutes later 
by induction of reflux esophagitis.
–  Group four (12 rats): Omeprazole (EIPICO, Egypt) was also dissolved in distilled 
water and given to rats before induction of reflux esophagitis. These rats were further 
subdivided into:
  4a (six rats): Omeprazole (60 mg/kg, orally) (24) was given to rats 30 minutes before 
in duction of reflux esophagitis.
  4b (six rats): Omepra zole was given before induction of reflux esophagitis in 
indometh acin treated rats. Rats received omeprazole (60 mg/kg orally) followed 30 
minutes later by in domethacin (5 mg/kg intraperitoneally) and finally 30 minutes later 
by induction of reflux esophagitis.
Quantification of gastric acid secretion
After sacrification, gastric contents were collected and centrifuged at 3000 g for 10 min at 
4 °C. After centrifugation, the supernatant gastric juice volumes (ml/rat), pH values (pH 
meter, Cyber Scan 500) (µEq/1) were measured. Acidities were determined by titration of 
gastric juice vs. 0.1 N NaOH to pH 7.0 and total acid outputs are expressed as µEq/h (24).
Determination of plasma nitric oxide (NO) level
A venous blood sample was withdrawn from rat tail veins into EDTA containing vials and 
centrifuged, for determination of NO concentration with QuantiChroM Nitric oxide Assay Kit 
(DINO-250) (Bioassay Systems, USA).
Biochemical assays of the esophageal mucosa
The esophageal mucosa was stripped of the muscle layer, and stored frozen at –70 °C for 
biochemical assays. Malondialdehyde (MDA) was determined in esophageal mucosa 
according to the method of Buege and Aust (10) colorimetrically.
GSH level was calorimetrically measured with Bioassay Systems’ QuantiChroM 
Glutathione Assay Kit (DIGT-250) (Bioassay Systems, USA) according to the manufacturer’s 
instructions.
Esophageal mucosal PGE2 concentration was determined using an immunoassay kit 
(R & D System, Inc., Minneapolis MN, USA).
Measurement of gross esophageal lesion
The esophagi were resected up to the upper segment close to the hypo pharynx. Then, they 
were cut along with the longitudinal axis. The lesion length (mm) that had developed in the 
esophagus was measured from the ruler using hand lens.
For examination of the macroscopic changes, the esophageal lesion score system was 
used from 0 to 3 and photographed. According to this macro scopic scoring, esophagus had 
score 0 for normal shimmering mucosa, 1 for hyperemic or edematous mucosa with focal 
hemorrhagic spots, 2 for multiple erosions with hematin attached, 3 for ulcerations and dark 
necrotic spots (17).
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Analysis of data
All data were compared by ANOVA followed by post hoc Tukey’s test, except the scoring 
method was determined by Kruskal–Wallis test followed by a Mann–Whitney test. The 
values were expressed as means ± SD. A p value of ≤ 0.05 was considered statistically 
significant. The statistical analysis was performed using the SPSS statistical Package version 
17.0 (SPSS, Chicago, IL, USA).
Results
Effects of BRL 37344, omeprazole on biochemical, macroscopic parameters in rats with 
induced reflux esophagitis (Table I):
Table I. Effects of BRL 37344 and omeprazole on biochemical parameters and macroscopic score in rats  
with induced reflux esophagitis (Mean ± SD) (n = 6)
Group 1a Group 2a Group 3a Group 4a
Acid output (µEq/h) 22.30 ± 1.2 216.83 ± 5.19a 153.66 ± 1.86abc 85.83 ± 1.83ab
PH 7.36 ± 0.19 1.46 ± 0.13a 3.68 ± 0.14abc 5.46 ± 0.25ab
Nitric oxide (µmol/L) 27.83 ± 1.16 37.50 ± 1.04a 46.50 ± 1.04abc 37.50 ± 1.04a
PGE2 (ng/g tissue) 133.16 ± 1.47 243.33 ± 1.86
 a 247.32 ± 1.36 a 244.33 ± 1.50 a
MDA (µM/g tissue) 0.40 ± 0.08 3.56 ± 0.10a 1.16 ± 0.12ab 1.50 ± 0.14ab
GSH (µM/g tissue) 184.33 ± 2.5 33 ± 0.89a 142.83 ± 2.13ab 145.50 ± 1.87ab
Damage score – 2.56 ± 0. 18a 1.50 ± 0.54ab 1.33 ± 0.51ab
Lesion length (mm) – 43.33 ± 2.16a 12.50 ± 1.51abc 22.33 ± 1.86ab
a versus group 1a, b versus group 2a, c versus group 4a
p < 0.05 was statistically significant
In RE group, gastric acid output, plasma nitric oxide (NO), mucosal PGE2 and MDA 
increased while pH, GSH decreased signifi cantly, relative to sham-operated rats (Figs 1 and 
2). Rats with RE had a significant macroscopic damage score of 2.66 ± 0.81 and lesion length 
43.33 ± 2.16 mm (p ≤ 0.05) (Figs 3 and 4), relative to sham-operated rats.
BRL 37344 group, showed a significant decrease in acid output, MDA, while a significant 
increase in pH, plasma NO, and GSH (p ≤ 0.05), with no significant effect (p ≥ 0.05) was 
shown on mucosal PGE2 relative to the RE group (Figs 1 and 2). In addition, there was a 
significant decrease in the macroscopic damage score, and lesion length (Figs 3 and 4).
Omeprazole group, showed a significant decrease in acid output, and MDA, increased 
pH and GSH, while no significant effect was shown on plasma NO and mucosal PGE2 (p ≥ 
0.05) relative to the RE group (Figs 1 and 2). Moreover, it decreased significantly the 
macroscopic damage score, and lesion length relative to the RE group (Figs 3 and 4).
Effects of BRL 37344, omeprazole on biochemical and macroscopic changes in 
indomethacin treated rats with induced reflux esophagitis (Table II).
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Table II. Effects of BRL 37344 and omeprazole on biochemical parameters and macroscopic score  
in indomethacin treated rats with induced reflux esophagitis (Mean ± SD) (n = 6)
Group 1b Group 2b Group 3b Group 4b
Acid output (µEq/h) 23.66 ± 1.36 245.50 ± 1.51a 146.83 ± 7.08abc 96.83 ± 1.94ab
PH 6.35 ± 0.74 1.23 ± 0.10a 3.48 ± 0.27abc 4.33 ± 0.81ab
Nitric oxide (µmol/L) 26.83 ± 1.16 21.83 ± 1.47a 27.66 ± 0.81b 22.66 ± 1.63a
PGE2 (ng/g tissue) 134.16 ± 2.48 84.83 ± 2.63a 92.16 ± 1.94a 85 ± 0.89a
MDA (µM/g tissue) 0.33 ± 0.12 3.48 ± 0.24a 0.80 ± 0.08ab 0.81 ± 0.09ab
GSH (µM/g tissue) 185.83 ± 3.06 34.33 ± 1.63a 143.66 ± 2.16abc 137 ± 1.41ab
Damage score – 2.66 ± 0.81a 0.43 ± 0.10abc 0.80 ± 0.08ab
Lesion length (mm) – 45.53 ± 1.55a 13.56 ± 0.38abc 21.83 ± 1.47ab
a versus group 1b, b versus group 2b, c versus group 3b
p < 0.05 was statistically significant
The RE experiments, in indomethacin-treated rats, gastric acid output, and MDA 
increased while pH, plasma NO, GSH and mucosal PGE2 decreased significantly relative to 
sham-operated rats (p ≤ 0.05) (Figs 4 and 5). Indomethacin-treated rats with induced RE had 
a significant macroscopic damage score of 2.56 ± 0.18 (Fig. 5) and lesion length 45.53 ± 
1.55 mm (p ≤ 0.05) (Fig. 6), relative to sham-operated rats.
BRL 37344 administration before induction of RE in indomethacin-treated rats 
significantly reduced acid output and MDA and it increased pH, NO and GSH (p ≤ 0.05) 
relative to the RE group (Figs 4 and 5). There was no significant increase in PGE2 (p ≥ 0.05) 
(Fig. 4). Moreover, it significantly decreased the macroscopic damage score and lesion length 
relative to the RE group (p ≤ 0.05) (Fig. 4).
Omeprazole administration before induction of RE in the indomethacin group 
significantly decreased acid output and MDA, while it increased pH and GSH (p ≤ 0.05 ) 
(Figs 4 and 5). No significant effect was shown on neither on NO levels or mucosal PGE2 (p ≥ 
0.05 ) relative to the RE group (Fig. 4). It also significantly reduced the macroscopic damage 
score, lesion length relative to the RE group (p ≤ 0.05) (Figs 5 and 6).
Discussion
RE is likely to be associated with impairment of different mechanisms as, endogenous NO 
release after an initial increment under gastric juice effect, cytokine expression and release of 
adhesion molecules (26). The calcium dependent neuronal nitric oxide synthase (nNOS) 
plays a physiological role in the gastrointestinal motility. Its dysfunction can lead to motility 
and lower esophageal sphincter disorders (22). Moreover, production of NO by endothelial 
nitric oxide synthase (eNOS) inhibits leucocytes aggregation and it is essential for the 
maintenance of esophageal mucosal blood flow. Oxygen free radicals are also implicated in 
the pathogenesis of reflux esophagitis (17, 18, 33).
This work evaluated the biochemical effects of the antiulcer drug BRL 37344, on reflux 
esophagitis with and without indomethacin administration.
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Fig. 1. Effects of BRL 37344 and omeprazole on biochemical parameters in rats with induced reflux esophagitis 
(Mean ± SD) (n = 6)
a versus group 1a, b versus group 2a, c versus group 4a
p ≤ 0.05 was statistically significant
Fig. 2. Effects of BRL 37344 and omeprazole on PH and MDA in rats with induced reflux esophagitis
(Mean ± SD) (n = 6)
a versus group 1a, b versus group 2a, c versus group 4a
p ≤ 0.05 was statistically significant
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Fig. 3. Effects of BRL 37344 and omeprazole on macroscopic score in rats with induced reflux esophagitis
(Mean ± SD) (n = 6)
a versus group 1a, b versus group 2a, c versus group 4a
p ≤ 0.05 was statistically significant
Fig. 4. Effects of BRL 37344 and omeprazole on biochemical parameters in indomethacin-treated rats with 
induced reflux esophagitis (Mean ± SD) (n = 6)
a versus group 1b, b versus group 2b, c versus group 3b
p ≤ 0.05 was statistically significant
101
Acta Physiologica Hungarica 102, 2015
BRL 37344 effect on reflux esophagitis
Fig. 5. Effects of BRL 37344 and omeprazole on PH, MDA and damage score in indomethacin-treated rats  
with induced reflux esophagitis (Mean ± SD) (n = 6)
a versus group 1b, b versus group 2b, c versus group 3b
p ≤ 0.05 was statistically significant
Fig. 6. Effect of BRL 37344 and omeprazole on lesion length (mm) in indomethacin-treated rats  
with induced reflux esophagitis (Mean ± SD) (n = 6)
a versus group 1b, b versus group 2b, c versus group 3b
p ≤ 0.05 was statistically significant
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Acute RE caused a significant increase in gastric acid output that resulted in a 
compensatory increase in plasma NO and PGE2 generation. This was associated with a 
decrease in pH. On the other hand, indomethacin a non-selective blocker of cyclooxygenase-
prostaglandin (COX/PG) system caused a dramatic suppression of PG and NO. This was 
associated with a significant increase in gastric acid output, decrease in pH.
The present results revealed that BRL 37344 administration, before induction of RE in 
rats with or without indomethacin, significantly decreased acid output, and increased pH. The 
role of NO was examined by Kato et al. (15) who have stated that NO reduces gastric acid 
secretion in basal and stimulated conditions. While Paul et al. (25) have also reported that a 
β3 agonist ZD 7114 and other agonists through β3 receptors, decrease gastric acid secretion, 
and they offer an esophagus protective activity against GERD via stimulation of the contractile 
activity of the lower esophageal sphincter leading to attenuation of the gastro-esophageal 
reflux (2, 29).
BRL 37344 also have shown a significant decrease in esophageal lipid peroxidation 
products (MDA) that were increased by RE, whereas, the depleted anti-oxidant glutathione 
observed in RE were replenished by its free radical scavenging and antioxidant effects, 
resulting in the improve ment of esophageal defense mechanism.
Barbier et al. (6) have reported that BRL 37344 has strong anti-inflammatory effect as it 
inhibits the expression of the proinflammatory cytokine TNF alpha in colitis.
Vasina et al. (31) have found that β3 agonists protect the gastrointestinal mucosa from 
oxidative damage and inflammation caused by TNF-alpha induced reactive oxygen species 
(ROS). Both CL 316234 and BRL 37344 produce an inhibitory effect on indomethacin 
induced antral gastric ulceration in a rat model of peptic ulcer and proposed a possible vaso 
dilator action of these drugs involved in their gastric mucosal protection (4).
Kato et al. (15) have found that BRL 37344 plays a protective, antistress role in the 
gastric mucosa via its vasodilator action and smooth muscle relaxant-like effect. β3 agonists 
stimulate bicarbonate secretion in the stomach and duodenum and have a role in repairing 
their ulcers (25).
Omeprazole administration significantly improved the pathogenesis and the biochemical 
changes of RE. Gastric acid secretion inhibition by proton pump inhibitors (PPI) as 
omeprazole is a vital step to control the RE disorder (28). They irreversible inhibit the H+-K+-
ATPase, the terminal proton pump of the parietal cell (27). They are converted to 
thiopHilicsulfenamide that reacts with the Cys-813 residue in the catalytic subunit of the 
H+-K+-ATPase, involved in enzyme inactivation (34).
Omeprazole plays a significant role in gastro protection by acting as a potent antioxidant 
and antiapoptotic molecule besides to the antisecretory action, and thus enhancing the ulcer 
healing process (9).
Suzuki et al. (30) have demonstrated that omeprazole, in vitro, modulates neutrophil 
function through inhibition of oxygen derived free radical synthesis and glucuronidase 
degradation. On the other hand, omeprazole still causes (and the other conventional anti-
ulcer drugs) many adverse effects and drug–drug interactions. These harmful effects may be 
the trigger point for looking for an alternative therapy (5, 9, 16, 19, 20, 32).
Conclusion
BRL 37344 (a selective β3 adrenoceptor agonist) has a protective effect on GERD through 
antioxidant-like effect which in turn decreases esophageal damage.
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